MeSH D020522 - mantle-cell lymphoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Bortezomib | Bortezomib |  | 2022-05-02 |  |  |
| Mylan | Bortezomib | Bortezomib |  | 2022-10-31 |  |  |
| Lenalidomide | Lenalidomide |  | 2022-08-30 |  |  | |
| Lenalidomide | Lenalidomide Mylan |  | 2020-12-18 |  |  | |
| Johnson & Johnson | Ibrutinib | Imbruvica |  | 2014-10-21 | $3,095 M | Q4/23-Q3/24 |
| Bortezomib | Velcade |  | 2004-04-26 | $408 M | Y2020 | |
| Roche | Rituximab | MabThera |  | 1998-06-02 |  |  |
| Cipla | Lenalidomide | Lenalidomide |  | 2022-09-06 |  |  |
| Sandoz | Bortezomib | Bortezomib |  | 2022-07-26 |  |  |
| Rituximab | Rixathon |  | 2017-06-15 |  |  | |
| Rituximab | Riximyo |  | 2017-06-15 |  |  | |
| AstraZeneca | Acalabrutinib | Calquence | 2026-11-24 | 2017-10-31 | $1,455 M | Q2/21-Q2/24 |
| Pfizer | Bortezomib | Bortezomib Hospira |  | 2016-07-22 |  |  |
| Rituximab | Ruxience |  | 2019-07-23 | $390 M | Y2023 | |
| Temsirolimus | Torisel |  | 2007-11-19 |  |  | |
| Takeda | Bortezomib | Velcade | 2022-01-25 | 2003-05-13 |  |  |
| Dr Reddys Laboratories | Bortezomib | Bortezomib |  | 2022-07-26 |  |  |
| Lenalidomide | Lenalidomide |  | 2021-10-14 |  |  |
1
2
3
4
5
>
Clinical Trials
Historical Success Rate
Phase 1
72%94/131
Phase 2
26%38/145
Phase 3
57%29/51
Approved: 11Overall Success rate: 11%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use